Stock Symbol:   

Stoxline Mobile
Home  |  Stock Charts  |  Showcases  |  Stock Ranks  |  Options  |  ETFs  |  Educations  |  Forex Crypto

Takeda Pharmaceutical Company Limited (TAK)

16.43   0.03 (0.18%) 03-22 16:00
Open: 16.36 Pre. Close: 16.4
High: 16.58 Low: 16.41
Volume: 1,968,336 Market Cap: 51,279(M)

Technical analysis

as of: 2023-03-22 3:51:48 PM
Stoxline posted a BUY today, upgraded from lower rating. Upward movement to be expected.
Target: Six months: 19.36     One year: 22.61
Support: Support1: 15.71    Support2: 15.18
Resistance: Resistance1: 16.57    Resistance2: 19.36
Pivot: 15.99
Moving Average: MA(5): 16.42     MA(20): 15.85
MA(100): 15.2     MA(250): 14.45
MACD: MACD(12,26): 0.1     Signal(9): 0.1
Stochastic oscillator: %K(14,3): 92.7     %D(3): 92.5
RSI: RSI(14): 68.5
52-week: High: 16.57  Low: 12.27
Average Vol(K): 3-Month: 2,730 (K)  10-Days: 2,848 (K)

Price, moving averages and Bollinger Bands

Price has closed above its short-term moving average. Short-term moving average is currently above mid-term; and above long-term moving average. From the relationship between price and moving averages: This stock is BULLISH in short-term; and BULLISH in mid-long term.
[ TAK ] has closed below upper band by 13.8%. Bollinger Bands are 40.1% wider than normal. The large width of the bands suggest high volatility as compared to its normal range. The bands have been in this wide range for 3 days. This is a sign that the current trend might continue.

Stock Price Prediction

Update at 5:00pm EST
If tomorrow: Open lower Open higher
High: 16.51 - 16.6 16.6 - 16.69
Low: 16 - 16.13 16.13 - 16.24
Close: 16.22 - 16.4 16.4 - 16.56

Company Description

Takeda Pharmaceutical Company Limited engages in the research, development, manufacture, marketing, and out-licensing of pharmaceutical products in Japan, the United States, Europe, Canada, Latin America, Russia, rest of Asia, and internationally. It offers pharmaceutical products in the areas of gastroenterology, rare diseases, plasma derived therapies, oncology, and neuroscience. The company provides its products under the Entyvio, Gattex/Revestive, Takecab, Alofisel, Dexilant, Natpara, Adynovate/Adynovi, Takhzyro, Livtencity, Elaprase, Replagal, Advate, Vpriv, Gammagard Liquid/Kiovig, Hyqvia, Cuvitru, Exkivity, Velcade, Leuplin/Enantone, Adcetris, Vyvansese, Trintellix, and Alunbrig brands. Takeda Pharmaceutical Company Limited has out-licensing agreement with Neurocrine Biosciences, Inc.; collaborations and in-licensing agreements with the University of Texas MD Anderson Cancer Center, Arrowhead Pharmaceuticals Inc., and Ovid Therapeutics Inc.; and collaboration with Evox Therapeutics Ltd., as well as a licensing agreement with ProThera Biologics Inc. It also has research collaboration and licensing agreement with Crescendo Biologics, Code Bio, Immusoft, Poseida Therapeutics, Selecta Biosciences, BridGene Biosciences, Skyhawk Therapeutics, and StrideBio; and strategic alliances with Egle Therapeutics SAS; Evotec SE; Neurocrine Biosciences, Inc.; Carmine Therapeutics; KSQ Therapeutics; and Anima Biotech. Takeda Pharmaceutical Company Limited was founded in 1781 and is headquartered in Tokyo, Japan.

Headline News

Tue, 21 Mar 2023
Dengue Fever Pipeline Assets Segmented by Stage, Product Type ... - Digital Journal

Tue, 21 Mar 2023
Price Growth & Yield: For That Magical Combo, Leave the U.S. - Nasdaq

Mon, 20 Mar 2023
AAD 2023: Takeda's TAK-297 hits endpoints in phase IIb psoriasis trial - BioWorld Online

Sun, 19 Mar 2023
Validea's Top Ten Healthcare Stocks Based On Martin Zweig - 3/19 ... - Nasdaq

Sat, 18 Mar 2023
Takeda Pharmaceutical Company Limited (NYSE:TAK) Shares Sold ... - MarketBeat

Sat, 18 Mar 2023
2023-03-18 | NYSE:TAK | Press Release | Takeda Pharmaceutical ... - Stockhouse

Financial Analysis

Price to Book Value: Outperform
P/BV, a ratio used to compare book value to its current market price, to gauge whether a stock is valued properly.
Price to Earnings: Outperform
PE, the ratio for valuing a company that measures its current share price relative to its earnings per share (EPS).
Discounted cash flow: Outperform
DCF, a valuation method used to estimate the value of an investment based on its expected future cash flows.
Return on Assets: Neutral
ROA, indicates how profitable a company is in relation to its total assets, how efficiently uses assets to generate a profit.
Return on Equity: Neutral
ROE, a measure of financial performance calculated by dividing net income by equity. a gauge of profitability and efficiency.
Debt to Equity: Outperform
evaluate financial leverage, reflects the ability of equity to cover outstanding debts in the event of a business downturn.
Free Technical Analysis Charts

Stock Basics & Statistics

Exchange:  NYSE
Sector:  Healthcare
Industry:  Drug Manufacturers—Specialty & Generic
Shares Out. 0 (M)
Shares Float 3,120 (M)
% Held by Insiders 3.07e+009 (%)
% Held by Institutions 0 (%)
Shares Short 6,160 (K)
Shares Short P.Month 0 (K)

Stock Financials

EPS 0.66
EPS Est Next Qtl 0
EPS Est This Year 0
EPS Est Next Year 0
Book Value (p.s.) 1
Profit Margin (%) 6.9
Operating Margin (%) 13.1
Return on Assets (ttm) 2.4
Return on Equity (ttm) 4.7
Qtrly Rev. Growth 21.7
Gross Profit (p.s.) 3.53
Sales Per Share 5.71
EBITDA (p.s.) 1.59
Qtrly Earnings Growth 106.8
Operating Cash Flow 0 (M)
Levered Free Cash Flow 0 (M)

Stock Valuations

PE Ratio 25.03
PEG Ratio 0
Price to Book value 16.52
Price to Sales 2.89
Price to Cash Flow 0.01

Stock Dividends

Dividend 0
Forward Dividend 5.03e+006
Dividend Yield 0%
Dividend Pay Date 2009-12-14
Ex-Dividend Date 2021-09-28
Your Ad Here
StockChart iOS
StoxlineLite iOS
StoxlineLite iOS
OptionCalc iOS
StockChart Android
StoxlineLite Android
StoxlinePro Android
OptionCalc Android
(c) 2006-2022 | Contact us           
Data and information is provided for informational purposes only, and is not intended for trading purposes. Neither nor its data provider shall be liable for any errors or delays in the content, or for any actions taken in reliance thereon. By accessing the web site, a user agrees not to redistribute the information found therein.